Hosted on MSN12h
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/YUltragenyx Pharmaceutical RARE reported fourth-quarter 2024 loss of $1.39 per share, wider than the Zacks Consensus Estimate ...
Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...
Who are the leading players in the Evkeeza market? Key players in the Evkeeza market include the notable Regeneron Pharmaceuticals Inc., contributing significantly to the market growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback